---
title: "Hemogenyx Pharma Plc (LON:HEMO) First-in-Human leukaemia treatment with HG-CT-1"
publisher: "Share Talk"
author: "sharetalk"
published: "2025-02-24T09:14:38+00:00"
modified: "2025-02-24T09:14:38+00:00"
date: 2025-02-24
canonical: "https://www.share-talk.com/hemogenyx-pharma-plc-lonhemo-first-in-human-leukaemia-treatment-with-hg-ct-1/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["biopharmaceutica", "Brain Cancers", "COVID-19", "Dr Vladislav Sandler", "Global Pharma", "gold rush", "H.C. Wainwright", "HEMO", "Hemogenyx", "Hemogenyx Pharma", "Neurodegenerative Diseases", "Pharma", "Share Talk", "Vladislav Sandler"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2024/02/HEMO-16_2_24.webp?fit=1200%2C800&quality=80&ssl=1"
format: "news"
language: "en-GB"
---

# Hemogenyx Pharma Plc (LON:HEMO) First-in-Human leukaemia treatment with HG-CT-1

**Published:** February 24, 2025
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** biopharmaceutica, Brain Cancers, COVID-19, Dr Vladislav Sandler, Global Pharma, gold rush, H.C. Wainwright, HEMO, Hemogenyx, Hemogenyx Pharma, Neurodegenerative Diseases, Pharma, Share Talk, Vladislav Sandler
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2024/02/HEMO-16_2_24.webp?fit=1200%2C800&quality=80&ssl=1)

---

**First-in-Human Treatment with HG-CT-1 for Relapsed or Refractory Acute Myeloid Leukemia**

**Hemogenyx Pharmaceuticals plc (LSE: HEMO)** is pleased to announce the administration of its first-in-human dose of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a major milestone in the Company’s clinical development program, demonstrating progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.

Further updates on the clinical trial will be provided in due course.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

“We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML.”

Enquiries:

Hemogenyx Pharmaceuticals plc

[https://hemogenyx.com](https://hemogenyx.com)

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[headquarters@hemogenyx.com](mailto:headquarters@hemogenyx.com)

---

**Original URL:** https://www.share-talk.com/hemogenyx-pharma-plc-lonhemo-first-in-human-leukaemia-treatment-with-hg-ct-1/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*